NCT05888857尚未招募2 期
A Multicentric Phase II Trial Evaluating MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 102
- 试验地点
- 1
- 主要终点
- Assessment of the antitumor activity of MEDI5752 (independently for eah cohort)
研究概览
简要总结
Multicentric, prospective, multi-indication, single-treatment arm, open-label phase II trial assessing the efficacy of MEDI5752
详细描述
Multicentric, prospective, multi-indication, single-treatment arm, open-label phase II trial assessing the efficacy of MEDI5752.
Patients with mature tertiary lymphoid structures advanced solid tumors will be included in two independent cohorts:
- Cohort A: patients with TLS+ IO-naïve solid tumor (miscellaneous)
- Cohort B: patients with TLS+ PD1/PDL1-experienced solid tumor (miscellaneous) Each cohort will rely on a two-stage three-outcome design as described in Sargent et al.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed solid tumor
- •IO-naïve patients (cohort A) OR patients with secondary resistance to PD1/PDL1 inhibitors (cohort B),
- •Patients in cohort B:
- •have to be diagnosed previously treated with PD-L1/PD-1 inhibitors (investigational or approved),
- •must have experienced initial clinical benefit (stable disease or better) from checkpoint inhibitor therapy for at least 4 months in which there was at least one interval scan prior to 4 months demonstrating no progression of disease.
- •Presence of mature tertiary lymphoid structures (TLS) by IHC as described in protocol section 3.2.
- •Except if presence of TLS has been already confirmed by Biopathological platform at Bergonié Institute, presence of TLS should be confirmed by central review based on FFPE tumor tissue sample,
- •Advanced unresectable or metastatic solid disease,
- •Measurable disease according to RECIST v1.1
- •At least one tumor site that can be biopsied for research purpose,
- •Age ≥ 18 years,
- •Body weight > 35 kg,
- •Life expectancy > 3 months,
- •Adequate hematological, renal, metabolic, hepatic and cardiac functions:
- •Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment. Note that no more than three lines of systemic treatment for metastatic disease are allowed and that patients with oncogenic addiction must have progressed on prior approved regimens),
- •Recovery to grade ≤ 1 from any adverse event derived from previous treatment (excluding alopecia of any grade (according to the NCI-CTCAE, version 5.0),
- •Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to study entry.
- •Women and men must agree to use at least one medically highly effective method of contraception from screening, throughout the treatment period
- •Voluntary signed and dated written informed consents prior to any specific study procedure,
- •Patients with a social security in compliance with the French law.
排除标准
- •Any anticancer treatment within 21 days or 5 half-lives (whichever is shorter) prior to start of study treatment,
- •Whole brain radiotherapy within 14 days prior to start of study treatment,
- •Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
- •Stereotactic radiosurgery within 7 days prior to start of study treatment,
- •Major surgery within 4 weeks prior to start of study treatment or still recovering from prior surgery
- •Men or women of childbearing potential who are not using an effective method of contraception as previously described; women who are pregnant or breast feeding,
- •History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study or confounds the ability to interpret data from the study
- •Prior or concurrent malignant disease
- •Any prior Grade ≥ 3 imAE while receiving immunotherapy or any unresolved imAE > Grade 1
- •For subjects who have received prior anti-PD-1, anti PD-L1 or anti CTLA-4 : Subject must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy, must not have experienced a ≥ grade 3 imAE or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy, must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, must not have experienced recurrence of an AE if rechallenged, and must not currently require maintenance doses of > 10 mg prednisone or equivalent per day
- •Symptomatic or actively progressing central nervous system metastases.
- •History of leptomeningeal disease or cord compression
- •Uncontrolled or symptomatic hypercalcemia
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, cardiomyopathy of any etiology, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, history of myocardial infarction within the past 12 months, cardiac arrhythmia, ILD, serious chronic gastrointestinal conditions associated with diarrhea,
- •Cerebrovascular accident within 6 months prior to enrolment,
- •Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
- •Active or history of autoimmune disease immune deficiency or inflammatory disorders, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, sarcoidosis syndrome, rheumatoid arthritis, hypophysitis, uveitis, inflammatory bowel disease, diverticulitis antiphospholipid antibody syndrome, Wegener granulomatosis, Graves'disease, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis,
- •History of idiopathic pulmonary fibrosis, organizing pneumonia drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening CT scan.
- •Evidence of the following infections: active infection including tuberculosis, HIV, active hepatitis B or C or A
- •Any contraindication to biopsy for the research,
- •Participation to a study involving a medical or therapeutic intervention in the last 30 days,
- •Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons,
- •Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia,
- •Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment.
- •Prior allogeneic stem cell or solid organ transplantation,
- •Treatment with a live, attenuated vaccine within 30 days prior to initiation of study treatment
- •Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic Immunosuppressive medication during study treatment,
- •History of severe allergic anaphylactic reaction to chimeric or humanized antibodies or fusion proteins,
- •Known hypersensitivity to Chinese hamster ovary cell products, to any component of the MEDI5752 formulation or to any human globulin therapy.
研究组 & 干预措施
Cohort A: patients with TLS+ IO-naïve solid tumors
Experimental
Participants with TLS+ IO-naïve solid tumors will be treated by MEDI5752
干预措施: MEDI5752 (Drug)
Cohort B: patients with TLS+ PD1/PDL1-experienced solid tumors
Experimental
Participants with TLS+ PD1/PDL1-experienced solid tumors will be treated by MEDI5752
干预措施: MEDI5752 (Drug)
结局指标
主要结局
Assessment of the antitumor activity of MEDI5752 (independently for eah cohort)
时间窗: an expected average of 6 months
Antitumor activity will be assessed in terms of objective response rate within 24 weeks based on RECIST v1.1, independently for each cohort, and based on centralized radiological review. Objective response under treatment is defined as patients with confirmed complete response or confirmed partial response, as per RECIST v1.1, observed during treatment with the investigational product. Objective response rate is defined as the proportion of patients alive with objective response based on RECIST v1.1. Objective response is recorded from study treatment initiation until the end of treatment.
次要结局
- 2-year progression-free survival (PFS), independently for each cohort(2 year)
- 24-weeks clinical benefit rate (CBR) independently for each cohort(24 weeks)
- Best overall response (BoR) independently for each cohort(Throughout the treatment period, an expected average of 6 months)
- 1-year overall survival (OS), independently for each cohort(1 year)
- Duration of response (DoR) independently for each cohort(Throughout the treatment period, an expected average of 6 months)
- 2-year overall survival (OS), independently for each cohort(2 year)
- Safety profile, independently for each cohort: Common Terminology Criteria for Adverse Events version 5(Throughout the treatment period, an expected average of 6 months)
- Duration of response (iDoR) independently for each cohort as per iRECIST(Throughout the treatment period, an expected average of 6 months)
- 1-year progression-free survival (iPFS), independently for each cohort as per iRECIST(1 year)
- 2-year progression-free survival (iPFS), independently for each cohort as per iRECIST(2 year)
- iORR independently for each cohort(Throughout the treatment period, an expected average of 6 months)
- 1-year progression-free survival (PFS), independently for each cohort(1 year)
- 24-weeks clinical benefit rate (iCBR) independently for each cohort as per iRECIST(24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR MutationsNSCLCNCT06029816Convalife (Shanghai) Co., Ltd.42
Unknown
2 期
Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPCNasopharyngeal CarcinomaNCT04421469Fujian Cancer Hospital39
尚未招募
2 期
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast CancerEarly Breast CancerNCT04659499Peking Union Medical College Hospital261
已完成
2 期
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell CarcinomaBasal Cell CarcinomaNCT00833417Genentech, Inc.104
进行中（未招募）
1 期
Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in patients with refractory/relapsed non-GCB diffuse large B-cell lymphoma non candidates to ASCTMedDRA version: 18.1Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851diffuse large B-cell lymphomaEUCTR2015-005390-21-ESGELTAMO64